The clinical significance of human leukocyte antigen antibody development in kidney transplantation

P. C. Lee, Y. L. Chen, T. C. Chou, W. M. Wang, Jung-Der Wang, Chung-Jye Hung, S. S. Chang, Yih-Jyh Lin, Ren-Hao Chan

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: This retrospective study uses the LAT-M (One Lambda Inc., Calif) screen assay to reexamine the impacts (a), of pretransplant human leukocyte antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA antibody on long-term graft survival and (c) immunosuppressive regimen on posttransplant HLA antibody development. Patients and methods: Pretransplant sera from 222 renal transplant recipients and posttransplant sera from 216 renal transplant recipients were studied for the impact of HLA antibody on long-term graft survival. Results: Among the patients who did not display pretransplant HLA antibodies, 85% enjoyed 5-year and 59% 10-year graft survival, whereas the patients who tested positive were 83% and 83% (P =.5596). Among the patients who did not show posttransplant HLA antibodies, 99% enjoyed 5-, 91% 10-, and 65% 15-year graft survival, whereas for the 44 patients who tested positive they were 59%, 44%, and 30%, respectively (P <.0001). Patients prescribed cyclosporine + myfortic (odds ratio 0.17, P =.05) or FK + Cellcept (odds ratio 0.36, P =.04) showed the lowest posttransplant HLA antibody development. Conclusion: Both regimens improve graft survival.

Original languageEnglish
Pages (from-to)264-266
Number of pages3
JournalTransplantation Proceedings
Volume44
Issue number1
DOIs
Publication statusPublished - 2012 Jan 1

Fingerprint

HLA Antigens
Kidney Transplantation
Graft Survival
Antibodies
Mycophenolic Acid
Odds Ratio
Kidney
Immunosuppressive Agents
Serum
Cyclosporine
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Surgery
  • Transplantation

Cite this

@article{01bde6d7d2a341e69dcd4182e9a88b8b,
title = "The clinical significance of human leukocyte antigen antibody development in kidney transplantation",
abstract = "Background: This retrospective study uses the LAT-M (One Lambda Inc., Calif) screen assay to reexamine the impacts (a), of pretransplant human leukocyte antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA antibody on long-term graft survival and (c) immunosuppressive regimen on posttransplant HLA antibody development. Patients and methods: Pretransplant sera from 222 renal transplant recipients and posttransplant sera from 216 renal transplant recipients were studied for the impact of HLA antibody on long-term graft survival. Results: Among the patients who did not display pretransplant HLA antibodies, 85{\%} enjoyed 5-year and 59{\%} 10-year graft survival, whereas the patients who tested positive were 83{\%} and 83{\%} (P =.5596). Among the patients who did not show posttransplant HLA antibodies, 99{\%} enjoyed 5-, 91{\%} 10-, and 65{\%} 15-year graft survival, whereas for the 44 patients who tested positive they were 59{\%}, 44{\%}, and 30{\%}, respectively (P <.0001). Patients prescribed cyclosporine + myfortic (odds ratio 0.17, P =.05) or FK + Cellcept (odds ratio 0.36, P =.04) showed the lowest posttransplant HLA antibody development. Conclusion: Both regimens improve graft survival.",
author = "Lee, {P. C.} and Chen, {Y. L.} and Chou, {T. C.} and Wang, {W. M.} and Jung-Der Wang and Chung-Jye Hung and Chang, {S. S.} and Yih-Jyh Lin and Ren-Hao Chan",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.transproceed.2011.11.037",
language = "English",
volume = "44",
pages = "264--266",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "1",

}

The clinical significance of human leukocyte antigen antibody development in kidney transplantation. / Lee, P. C.; Chen, Y. L.; Chou, T. C.; Wang, W. M.; Wang, Jung-Der; Hung, Chung-Jye; Chang, S. S.; Lin, Yih-Jyh; Chan, Ren-Hao.

In: Transplantation Proceedings, Vol. 44, No. 1, 01.01.2012, p. 264-266.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The clinical significance of human leukocyte antigen antibody development in kidney transplantation

AU - Lee, P. C.

AU - Chen, Y. L.

AU - Chou, T. C.

AU - Wang, W. M.

AU - Wang, Jung-Der

AU - Hung, Chung-Jye

AU - Chang, S. S.

AU - Lin, Yih-Jyh

AU - Chan, Ren-Hao

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Background: This retrospective study uses the LAT-M (One Lambda Inc., Calif) screen assay to reexamine the impacts (a), of pretransplant human leukocyte antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA antibody on long-term graft survival and (c) immunosuppressive regimen on posttransplant HLA antibody development. Patients and methods: Pretransplant sera from 222 renal transplant recipients and posttransplant sera from 216 renal transplant recipients were studied for the impact of HLA antibody on long-term graft survival. Results: Among the patients who did not display pretransplant HLA antibodies, 85% enjoyed 5-year and 59% 10-year graft survival, whereas the patients who tested positive were 83% and 83% (P =.5596). Among the patients who did not show posttransplant HLA antibodies, 99% enjoyed 5-, 91% 10-, and 65% 15-year graft survival, whereas for the 44 patients who tested positive they were 59%, 44%, and 30%, respectively (P <.0001). Patients prescribed cyclosporine + myfortic (odds ratio 0.17, P =.05) or FK + Cellcept (odds ratio 0.36, P =.04) showed the lowest posttransplant HLA antibody development. Conclusion: Both regimens improve graft survival.

AB - Background: This retrospective study uses the LAT-M (One Lambda Inc., Calif) screen assay to reexamine the impacts (a), of pretransplant human leukocyte antigen (HLA) antibody on long-term graft survival; (b) posttransplant HLA antibody on long-term graft survival and (c) immunosuppressive regimen on posttransplant HLA antibody development. Patients and methods: Pretransplant sera from 222 renal transplant recipients and posttransplant sera from 216 renal transplant recipients were studied for the impact of HLA antibody on long-term graft survival. Results: Among the patients who did not display pretransplant HLA antibodies, 85% enjoyed 5-year and 59% 10-year graft survival, whereas the patients who tested positive were 83% and 83% (P =.5596). Among the patients who did not show posttransplant HLA antibodies, 99% enjoyed 5-, 91% 10-, and 65% 15-year graft survival, whereas for the 44 patients who tested positive they were 59%, 44%, and 30%, respectively (P <.0001). Patients prescribed cyclosporine + myfortic (odds ratio 0.17, P =.05) or FK + Cellcept (odds ratio 0.36, P =.04) showed the lowest posttransplant HLA antibody development. Conclusion: Both regimens improve graft survival.

UR - http://www.scopus.com/inward/record.url?scp=84863355769&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863355769&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.11.037

DO - 10.1016/j.transproceed.2011.11.037

M3 - Article

VL - 44

SP - 264

EP - 266

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 1

ER -